These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 20497963)

  • 1. Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients.
    Ronzoni M; Manzoni M; Mariucci S; Loupakis F; Brugnatelli S; Bencardino K; Rovati B; Tinelli C; Falcone A; Villa E; Danova M
    Ann Oncol; 2010 Dec; 21(12):2382-2389. PubMed ID: 20497963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab.
    Simkens LHJ; Tol J; Terstappen LWMM; Teerenstra S; Punt CJA; Nagtegaal ID
    Ann Oncol; 2010 Dec; 21(12):2447-2448. PubMed ID: 21030382
    [No Abstract]   [Full Text] [Related]  

  • 3. Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab.
    Matsusaka S; Mishima Y; Suenaga M; Terui Y; Kuniyoshi R; Mizunuma N; Hatake K
    Cancer; 2011 Sep; 117(17):4026-32. PubMed ID: 21858803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.
    Malka D; Boige V; Jacques N; Vimond N; Adenis A; Boucher E; Pierga JY; Conroy T; Chauffert B; François E; Guichard P; Galais MP; Cvitkovic F; Ducreux M; Farace F
    Ann Oncol; 2012 Apr; 23(4):919-27. PubMed ID: 21825101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
    Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
    Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer.
    Manzoni M; Mariucci S; Delfanti S; Rovati B; Ronzoni M; Loupakis F; Brugnatelli S; Tinelli C; Villa E; Falcone A; Danova M
    J Cancer Res Clin Oncol; 2012 Jul; 138(7):1187-96. PubMed ID: 22419441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer.
    Hansen TF; Carlsen AL; Heegaard NH; Sørensen FB; Jakobsen A
    Br J Cancer; 2015 Feb; 112(4):624-9. PubMed ID: 25584492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
    Avallone A; Piccirillo MC; Aloj L; Nasti G; Delrio P; Izzo F; Di Gennaro E; Tatangelo F; Granata V; Cavalcanti E; Maiolino P; Bianco F; Aprea P; De Bellis M; Pecori B; Rosati G; Carlomagno C; Bertolini A; Gallo C; Romano C; Leone A; Caracò C; de Lutio di Castelguidone E; Daniele G; Catalano O; Botti G; Petrillo A; Romano GM; Iaffaioli VR; Lastoria S; Perrone F; Budillon A
    BMC Cancer; 2016 Feb; 16():69. PubMed ID: 26857924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma.
    DuBois SG; Stempak D; Wu B; Mokhtari RB; Nayar R; Janeway KA; Goldsby R; Grier HE; Baruchel S
    Pediatr Blood Cancer; 2012 Feb; 58(2):181-4. PubMed ID: 21319292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer.
    Matsusaka S; Suenaga M; Mishima Y; Takagi K; Terui Y; Mizunuma N; Hatake K
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):763-8. PubMed ID: 21170650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness.
    Bencsikova B; Budinska E; Selingerova I; Pilatova K; Fedorova L; Greplova K; Nenutil R; Valik D; Obermannova R; Sheard MA; Zdrazilova-Dubska L
    BMC Cancer; 2019 Jul; 19(1):687. PubMed ID: 31307428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.
    Ikeda S; Kato T; Ogura T; Sekine A; Oda T; Masuda N; Igawa S; Katono K; Otani S; Yamada K; Saito H; Kondo T; Hosomi Y; Nakahara Y; Nishikawa M; Utumi K; Misumi Y; Yamanaka T; Sakamaki K; Okamoto H
    BMC Cancer; 2018 Mar; 18(1):241. PubMed ID: 29499653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
    García-Carbonero R; van Cutsem E; Rivera F; Jassem J; Gore I; Tebbutt N; Braiteh F; Argiles G; Wainberg ZA; Funke R; Anderson M; McCall B; Stroh M; Wakshull E; Hegde P; Ye W; Chen D; Chang I; Rhee I; Hurwitz H
    Oncologist; 2017 Apr; 22(4):375-e30. PubMed ID: 28275117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET).
    Vasseur A; Cabel L; Tredan O; Chevrier M; Dubot C; Lorgis V; Jacot W; Goncalves A; Debled M; Levy C; Ferrero JM; Jouannaud C; Luporsi E; Mouret-Reynier MA; Dalenc F; Lemonnier J; Savignoni A; Tanguy ML; Bidard FC; Pierga JY
    Angiogenesis; 2020 May; 23(2):193-202. PubMed ID: 31773439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.
    Prager GW; Braemswig KH; Martel A; Unseld M; Heinze G; Brodowicz T; Scheithauer W; Kornek G; Zielinski CC
    Cancer Sci; 2014 Aug; 105(8):996-1001. PubMed ID: 24850362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.
    Cuppini L; Calleri A; Bruzzone MG; Prodi E; Anghileri E; Pellegatta S; Mancuso P; Porrati P; Di Stefano AL; Ceroni M; Bertolini F; Finocchiaro G; Eoli M
    PLoS One; 2013; 8(9):e74345. PubMed ID: 24069296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
    Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
    Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
    Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
    Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.